Samsung Biologics made an all-cash tender offer of about $1.8 billion to acquire PolyPeptide Group, a Switzerland-based CDMO focused on peptide APIs. The move expands Samsung’s manufacturing beyond antibodies and ADCs into peptide therapeutics, including peptide-heavy categories like obesity and diabetes. The transaction centers on building an end-to-end, multi-modality CDMO platform by combining Samsung’s global scale with PolyPeptide’s peptide development-to-commercial capabilities across multiple sites. PolyPeptide’s history includes large-scale manufacturing of thousands of therapeutic peptides, giving Samsung a foundation in peptide chemistry and production. For the broader market, the bid reinforces that peptides—particularly GLP-1-adjacent modalities and next-generation peptide drugs—are drawing manufacturing capacity investment comparable to biologics and ADCs.